Theriva Biologics, Inc

Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patients immune system. The Companys lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade...

Microbiome,prevention of c. dificile infection,irritable bowel syndrome with constipation (ibs-c),clinical development,drug discovery,preservation of natural gut microbiome,oncology,oncolytic virus,and cancer

Theriva biologics, inc operates in the Biotechnology research industry.

Theriva biologics, inc's revenue is 11m - 100m

Theriva biologics, inc has 11 - 50 employees.